Scientists presenting at the American Association for Cancer Research Annual Meeting in Chicago have found new and promising ways to use immunotherapy to treat people with some types of non-small cell lung cancer (NSCLC).

The US Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for people with stage III (3) non-small cell lung cancer who are not able to be treated with surgery to remove their tumor, and whose cancer has not gotten worse after they received chemotherapy along with radiation (chemoradiation).